查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542674

重症加护治疗的全球市场

Critical Care Therapeutics
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 280 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球重症加护治疗市场预计将达到 74 亿美元

2023年全球重症加护治疗市场估计为50亿美元，预计到2030年将达到74亿美元，2023-2030年分析期间复合年增长率为5.6%。白蛋白药物类是本报告分析的细分市场之一，复合年增长率为 6.9%，预计到分析期结束时将达到 37 亿美元。在分析期间，富含凝血酶复合物的药物类别细分市场的复合年增长率预计为 4.6%。

美国市场预估成长13亿美元，中国复合年增长率为9.0%

到 2023 年，美国重症加护治疗市场预计将达到 13 亿美元。中国作为世界第二大经济体，预计2030年市场规模将达18亿美元，2023-2030年分析期间复合年增长率为9.0%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 3.1% 和 4.4%。在欧洲，德国的复合年增长率预计为 4.0%。

全球重症加护治疗市场—主要趋势和驱动因素总结

生存危机：重症加护治疗将如何彻底改变加护治疗？

重症加护治疗包括专为加护病房(ICU) 中面临危及生命健康状况的患者设计的各种治疗方法。这些治疗包括先进的药物干预、血液製品和客製化的生命维持措施，以管理可能导致多重器官衰竭的急性疾病。主要目标是稳定重要功能并防止进一步恶化，直到可以康復。这些疗法对于败血症、急性呼吸窘迫症候群(ARDS)、心臟衰竭和其他严重的治疗至关重要。促效剂、抗凝血剂、抗生素、皮质类固醇和其他药物通常用于支持处于严重压力的器官系统。

哪些创新正在塑造重症加护治疗领域？

重症加护疗法的创新对于改善 ICU 等恶劣环境中的患者治疗效果至关重要。最近的趋势包括开发更有针对性的药物疗法，这些疗法可提供更高的疗效和更少的副作用。例如，精准医学方法的引入使得治疗能够基于个别基因图谱，从而有可能改善重症患者的治疗结果。此外，使用单株抗体和重组蛋白等生物製药来治疗脓毒症等疾病开闢了解决严重根本原因的新途径，而不仅仅是控制症状。这些创新得到了对严重状态病理学的持续研究的支持，为持续改进治疗优化提供了基础。

哪些挑战会影响重症加护治疗的有效性？

儘管取得了重大进展，但仍有一些挑战影响了重症加护治疗的有效性。患者对治疗反应的巨大差异使重症患者的管理变得复杂，并且可能使标准化治疗方案无效。重症加护环境也面临独特的挑战，包括疾病快速进展和併发症高风险，需要高度动态和反应灵敏的治疗策略。此外，抗菌药物抗药性的风险对有效治疗感染疾病构成严重威胁，特别是在经常使用广效抗生素的环境中。应对这些挑战需要采取多学科方法，并根据最新的临床证据和治疗技术不断调整治疗通讯协定。

推动重症加护治疗市场成长的关键因素是什么？

重症加护治疗市场的成长是由多种因素推动的，这些因素反映了重症加护的复杂而紧迫的需求。由于人口老化和导致严重的慢性病盛行率上升，全球医疗保健需求不断增加，是重要的成长动力。最近的全球卫生事件，例如 COVID-19 大流行，也大大增加了对有效重症加护治疗的需求，并凸显了对能够应对严重急性疾病的强大卫生系统的需求。医学研究的进步导致新药和治疗方法的发现，也有助于市场的扩张。此外，全球医疗保健支出的增加，特别是在新兴经济体，正在推动 ICU 中先进治疗解决方案的采用。总的来说，这些因素支持了重症加护治疗领域的持续发展和扩展，凸显了其在全球医疗基础设施中的重要角色。

受访企业范例（共37家）

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd.
  • Asklepios Biopharmaceutical, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Baxter International Inc.
  • Bayer Healthcare AG
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • Biotest Pharmaceuticals Corporation
  • Bristol-Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • China Biologic Products Holdings, Inc.
  • Cosmo Pharmaceuticals NV
  • CSL Behring
  • Grifols International SA
  • Kamada Ltd.
  • Kedrion Biopharma, Inc.
  • Medxbio Pte. Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novo Nordisk A/S
  • Novozymes A/S
  • Octapharma AG
  • Portola Pharmaceuticals, Inc.
  • ProMetic Life Sciences, Inc.
  • rEVO Biologics, Inc.
  • Rockwell Medical
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.
  • The Medicines Company
  • Thermo Fisher Scientific, Inc.
  • Ventria Bioscience

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 比赛

简介目录
Product Code: MCP11369

Global Critical Care Therapeutics Market to Reach US$7.4 Billion by 2030

The global market for Critical Care Therapeutics estimated at US$5.0 Billion in the year 2023, is expected to reach US$7.4 Billion by 2030, growing at a CAGR of 5.6% over the analysis period 2023-2030. Albumin Drug Class, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$3.7 Billion by the end of the analysis period. Growth in the Prothrombin Complex Concentrates Drug Class segment is estimated at 4.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 9.0% CAGR

The Critical Care Therapeutics market in the U.S. is estimated at US$1.3 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$1.8 Billion by the year 2030 trailing a CAGR of 9.0% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 4.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.0% CAGR.

Global Critical Care Therapeutics Market - Key Trends and Drivers Summarized

At the Edge of Survival: How Are Critical Care Therapeutics Revolutionizing Intensive Care?

Critical care therapeutics encompass a range of medical treatments specifically designed for patients in intensive care units (ICUs) who are facing life-threatening health conditions. These treatments include advanced pharmacological interventions, blood products, and life-support measures tailored to manage acute illnesses that can lead to multiple organ failure. The primary goal is to stabilize vital functions and prevent further deterioration until recovery becomes feasible. These therapeutics are integral in the management of sepsis, acute respiratory distress syndrome (ARDS), cardiac failures, and other critical conditions. They often involve the use of vasoactive drugs, anticoagulants, antibiotics, corticosteroids, and other agents that support organ systems under severe stress.

What Innovations Are Shaping the Field of Critical Care Therapeutics?

Innovation in critical care therapeutics is crucial in improving patient outcomes in environments as challenging as the ICU. Recent advancements include the development of more targeted drug therapies that offer higher efficacy with fewer side effects. For instance, the introduction of precision medicine approaches allows for treatments based on individual genetic profiles, potentially enhancing the therapeutic outcomes for critically ill patients. Additionally, the use of biologics—such as monoclonal antibodies and recombinant proteins—to treat conditions like sepsis has opened new avenues for addressing the underlying causes of critical illnesses rather than just managing symptoms. These innovations are supported by ongoing research into the pathophysiology of critical conditions, providing a continuously improving basis for therapy optimization.

What Challenges Impact the Efficacy of Critical Care Therapeutics?

Despite significant advancements, several challenges impact the efficacy of critical care therapeutics. The high variability in patient responses to treatments can complicate the management of critical illnesses, making standardized treatment protocols less effective. The critical care environment also presents unique challenges, such as the rapid progression of diseases and the high risk of complications, which require exceptionally dynamic and responsive treatment strategies. Moreover, the risk of antimicrobial resistance, particularly in settings where broad-spectrum antibiotics are frequently used, poses a serious threat to treating infections effectively. Addressing these challenges requires a multidisciplinary approach and continuous adaptation of treatment protocols based on the latest clinical evidence and therapeutic technologies.

What Are the Key Drivers Propelling the Growth of the Critical Care Therapeutics Market?

The growth in the critical care therapeutics market is driven by several factors, reflecting the complex and urgent nature of critical care needs. Increasing global healthcare demands due to a rising aging population and higher prevalence of chronic diseases that can lead to critical illness are significant growth drivers. The recent global health events, such as the COVID-19 pandemic, have also dramatically increased the demand for effective critical care therapeutics, highlighting the need for robust health systems capable of managing severe acute conditions. Advances in medical research that lead to new drug discoveries and therapeutic approaches contribute to market expansion as well. Furthermore, increased healthcare spending worldwide, especially in emerging economies, supports the adoption of advanced therapeutic solutions in ICUs. These factors collectively fuel the ongoing development and expansion of the critical care therapeutics sector, underscoring its vital role in global health infrastructure.

Select Competitors (Total 37 Featured) -

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd.
  • Asklepios Biopharmaceutical, Inc.
  • Aspen Pharmacare Holdings Ltd.
  • Baxter International Inc.
  • Bayer Healthcare AG
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biogen, Inc.
  • BioMarin Pharmaceutical Inc.
  • Biotest Pharmaceuticals Corporation
  • Bristol-Myers Squibb Company
  • Catalyst Biosciences, Inc.
  • China Biologic Products Holdings, Inc.
  • Cosmo Pharmaceuticals NV
  • CSL Behring
  • Grifols International SA
  • Kamada Ltd.
  • Kedrion Biopharma, Inc.
  • Medxbio Pte. Ltd.
  • Merck & Co., Inc.
  • Mitsubishi Tanabe Pharma Corporation
  • Novo Nordisk A/S
  • Novozymes A/S
  • Octapharma AG
  • Portola Pharmaceuticals, Inc.
  • ProMetic Life Sciences, Inc.
  • rEVO Biologics, Inc.
  • Rockwell Medical
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire PLC
  • Teva Pharmaceutical Industries Ltd.
  • The Medicines Company
  • Thermo Fisher Scientific, Inc.
  • Ventria Bioscience

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Critical Care Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
    • Global Economic Update
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Incidence of Chronic Diseases Drives Demand for Critical Care Therapeutics
    • Advancements in Biotechnology Propel Development of Innovative Critical Care Drugs
    • Increased Investment in Healthcare Infrastructure Supports Critical Care Therapeutic Availability
    • Growing Geriatric Population Bolsters Market for Age-Specific Therapeutic Solutions
    • Rise in Healthcare Expenditure Worldwide Sustains Growth in Therapeutic Development
    • Demand for Multifunctional Drugs Amplifies Development of Combination Therapies
    • Technological Advances in Drug Delivery Systems Enhance Critical Care Management
    • Health Insurance Coverage Influence Therapeutic Adoption
    • Expansion of Emergency Care Units Worldwide Drives Need for Advanced Therapeutics
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Critical Care Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Albumin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Albumin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Prothrombin Complex Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Prothrombin Complex Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Prothrombin Complex Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Antithrombin Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Antithrombin Concentrates by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Antithrombin Concentrates by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Deep Vein Thrombosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Deep Vein Thrombosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Pulmonary Embolism (PE) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Pulmonary Embolism (PE) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Acute Coronary Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Acute Coronary Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 28: World Critical Care Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Critical Care Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • FRANCE
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: France 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Critical Care Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: India 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Critical Care Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Critical Care Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Critical Care Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Critical Care Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Critical Care Therapeutics by Drug Class - Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Critical Care Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates and Other Drug Classes for the Years 2014, 2024 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Critical Care Therapeutics by Application - Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Critical Care Therapeutics by Application - Percentage Breakdown of Value Sales for Deep Vein Thrombosis, Pulmonary Embolism (PE), Acute Coronary Syndrome and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION